{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:28:25Z","timestamp":1793755705638,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s11060-026-05826-7","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:13:03Z","timestamp":1791670383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative dosing of bevacizumab for radiation necrosis: impact of tumor type on edema response"],"prefix":"10.1007","volume":"180","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9689-8123","authenticated-orcid":false,"given":"Sydney E.","family":"Schultz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milisia","family":"Labib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Breit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason N.","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Mead-Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Behair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin","family":"Nurioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Valerius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishika","family":"Karbhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"Taraba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Soefje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gena","family":"Hoefs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha J.","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon H.","family":"Uhm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Lachance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sani H.","family":"Kizilbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian L.","family":"Campian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan J.","family":"Neth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur","family":"Sener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"issue":"Suppl 1","key":"5826_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2176\/nmc.ra.2014-0188","volume":"55","author":"S Miyatake","year":"2015","unstructured":"Miyatake S, Nonoguchi N, Furuse M, Yoritsune E, Miyata T, Kawabata S, Kuroiwa T (2015) Pathophysiology, Diagnosis, and Treatment of Radiation Necrosis in the Brain. Neurol Med Chir (Tokyo) 55(Suppl 1):50\u201359","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"5826_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1188\/26.CJON.181-185","volume":"30","author":"ME Davis","year":"2026","unstructured":"Davis ME, Quebec S (2026) Radiation Necrosis: A Differential Diagnosis Dilemma. Clin J Oncol Nurs 30:181\u2013185. https:\/\/doi.org\/10.1188\/26.CJON.181-185","journal-title":"Clin J Oncol Nurs"},{"key":"5826_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/0360-3016(81)90443-0","volume":"7","author":"JE Marks","year":"1981","unstructured":"Marks JE, Baglan RJ, Prassad SC, Blank WF (1981) Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume. Int J Radiat Oncol Biol Phys 7:243\u2013252. https:\/\/doi.org\/10.1016\/0360-3016(81)90443-0","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5826_CR4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1159\/000411642","volume":"29","author":"JE Marks","year":"1985","unstructured":"Marks JE, Wong J (1985) The risk of cerebral radionecrosis in relation to dose, time and fractionation. A follow-up study. Prog Exp Tumor Res 29:210\u2013218. https:\/\/doi.org\/10.1159\/000411642","journal-title":"Prog Exp Tumor Res"},{"key":"5826_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ijrobp.2005.12.002","volume":"65","author":"JD Ruben","year":"2006","unstructured":"Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P (2006) Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 65:499\u2013508. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.12.002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5826_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/00006123-200108000-00026","volume":"49","author":"T Kamiryo","year":"2001","unstructured":"Kamiryo T, Lopes MB, Kassell NF, Steiner L, Lee KS (2001) Radiosurgery-induced microvascular alterations precede necrosis of the brain neuropil. Neurosurgery 49:409\u2013414 discussion 414\u2009\u2013\u2009405. https:\/\/doi.org\/10.1097\/00006123-200108000-00026","journal-title":"Neurosurgery"},{"key":"5826_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11060-011-0610-9","volume":"105","author":"N Nonoguchi","year":"2011","unstructured":"Nonoguchi N, Miyatake S, Fukumoto M, Furuse M, Hiramatsu R, Kawabata S, Kuroiwa T, Tsuji M, Fukumoto M, Ono K (2011) The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles. J Neurooncol 105:423\u2013431. https:\/\/doi.org\/10.1007\/s11060-011-0610-9","journal-title":"J Neurooncol"},{"key":"5826_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/neup.12958","volume":"44","author":"F Takagi","year":"2024","unstructured":"Takagi F, Furuse M, Kuwabara H, Kambara A, Omura N, Tanabe S, Yagi R, Hiramatsu R, Kameda M, Nonoguchi N, Kawabata S, Takami T, Miyatake SI, Wanibuchi M (2024) Expression and distribution of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in comparison between radiation necrosis and tumor tissue in metastatic brain tumor: A case report. Neuropathology 44:240\u2013246. https:\/\/doi.org\/10.1111\/neup.12958","journal-title":"Neuropathology"},{"key":"5826_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12943-019-0950-1","volume":"18","author":"H Zhuang","year":"2019","unstructured":"Zhuang H, Shi S, Yuan Z, Chang JY (2019) Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues. Mol Cancer 18:21. https:\/\/doi.org\/10.1186\/s12943-019-0950-1","journal-title":"Mol Cancer"},{"key":"5826_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","volume":"15","author":"M Oray","year":"2016","unstructured":"Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS (2016) Long-term side effects of glucocorticoids. Expert Opin Drug Saf 15:457\u2013465. https:\/\/doi.org\/10.1517\/14740338.2016.1140743","journal-title":"Expert Opin Drug Saf"},{"key":"5826_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","volume":"7","author":"Y Wang","year":"2004","unstructured":"Wang Y, Fei D, Vanderlaan M, Song A (2004) Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7:335\u2013345. https:\/\/doi.org\/10.1007\/s10456-004-8272-2","journal-title":"Angiogenesis"},{"key":"5826_CR12","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL (2020) Bevacizumab (Avastin(R)) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev 86:102017. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102017","journal-title":"Cancer Treat Rev"},{"key":"5826_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11060-024-04916-8","volume":"172","author":"S Lim","year":"2025","unstructured":"Lim S, Clarke NH, Maloney SL, Sener UT, Caron SJ, Kizilbash SH, Campian JL, Neth BJ, Carabenciov ID, Uhm J, Ruff MW (2025) Bevacizumab exerts dose-dependent risk for intracranial hemorrhage in patients with malignant gliomas. J Neurooncol 172:273\u2013280. https:\/\/doi.org\/10.1007\/s11060-024-04916-8","journal-title":"J Neurooncol"},{"key":"5826_CR14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1080\/01616412.2025.2528155","volume":"48","author":"H Li","year":"2026","unstructured":"Li H, Qi B, He Y, Pan D, Li Y, Xu Y, Tang Y (2026) Efficacy and safety of low-dose vs medium-dose bevacizumab for radiation-induced brain necrosis in nasopharyngeal carcinoma survivors. Neurol Res 48:300\u2013309. https:\/\/doi.org\/10.1080\/01616412.2025.2528155","journal-title":"Neurol Res"},{"key":"5826_CR15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4103\/aian.aian_645_24","volume":"28","author":"BV Maramattom","year":"2025","unstructured":"Maramattom BV (2025) Symptomatic Bevacizumab-Induced Cerebral Infarction Following Treatment for Radiation Necrosis. Ann Indian Acad Neurol 28:278\u2013280. https:\/\/doi.org\/10.4103\/aian.aian_645_24","journal-title":"Ann Indian Acad Neurol"},{"key":"5826_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11060-025-04979-1","volume":"173","author":"H Nobel","year":"2025","unstructured":"Nobel H, Ofer J, Borenstein SF, Limon D, Gal O, Laviv Y, Kanner AA, Siegal T, Yust-Katz S, Benouaich-Amiel A (2025) Long-term impact of bevacizumab for the treatment of brain radiation necrosis. J Neurooncol 173:289\u2013296. https:\/\/doi.org\/10.1007\/s11060-025-04979-1","journal-title":"J Neurooncol"},{"key":"5826_CR17","doi-asserted-by":"publisher","first-page":"13265","DOI":"10.18632\/oncotarget.7724","volume":"7","author":"H Zhuang","year":"2016","unstructured":"Zhuang H, Yuan X, Sun D, Bian J, Chang JY, Yuan Z, Wang P (2016) Acquired-resistance of bevacizumab treatment for radiation brain necrosis: a case report. Oncotarget 7:13265\u201313268. https:\/\/doi.org\/10.18632\/oncotarget.7724","journal-title":"Oncotarget"},{"key":"5826_CR18","doi-asserted-by":"publisher","first-page":"vdad123","DOI":"10.1093\/noajnl\/vdad123","volume":"5","author":"MJ Webb","year":"2023","unstructured":"Webb MJ, Neth BJ, Webb LM, Van Gompel JJ, Link MJ, Neff BA, Carlson ML, Driscoll CL, Dornhoffer J, Ruff MW, Anderson KA, Kizilbash SH, Campian JL, Uhm JH, Lane JI, Benson JC, Blezek DJ, Mehta PM, Bathla G, Sener UT (2023) Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients. Neurooncol Adv 5:vdad123. https:\/\/doi.org\/10.1093\/noajnl\/vdad123","journal-title":"Neurooncol Adv"},{"key":"5826_CR19","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/nop\/npaf059","volume":"12","author":"LL Kroon","year":"2025","unstructured":"Kroon LL, Dieleman EMT, Keil VC, van Barreveld M, Dijkgraaf MGW, Topff L, Wagemakers SN, Snijders TJ, Vos MJ, Koekkoek JAF, Stalpers LJA, de Vos F, Brandsma D (2025) Bevacizumab for symptomatic cerebral radiation necrosis after radiation of high-grade glioma or brain metastases - when and for whom? Neurooncol Pract 12:747\u2013762. https:\/\/doi.org\/10.1093\/nop\/npaf059","journal-title":"Neurooncol Pract"},{"key":"5826_CR20","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3340\/jkns.2022.0229","volume":"66","author":"SH Lee","year":"2023","unstructured":"Lee SH, Choi JW, Kong DS, Seol HJ, Nam DH, Lee JI (2023) Effect of Bevacizumab Treatment in Cerebral Radiation Necrosis: Investigation of Response Predictors in a Single-Center Experience. J Korean Neurosurg Soc 66:562\u2013572. https:\/\/doi.org\/10.3340\/jkns.2022.0229","journal-title":"J Korean Neurosurg Soc"},{"key":"5826_CR21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cllc.2024.06.010","volume":"25","author":"D Shibahara","year":"2024","unstructured":"Shibahara D, Tanaka K, Togao O, Shiraishi Y, Yoneshima Y, Iwama E, Yoshitake T, Ishigami K, Okamoto I (2024) Bevacizumab for Brain Radiation Necrosis in Patients With Nonsquamous Nonsmall Cell Lung Cancer. Clin Lung Cancer 25:581\u2013586e583. https:\/\/doi.org\/10.1016\/j.cllc.2024.06.010","journal-title":"Clin Lung Cancer"},{"key":"5826_CR22","doi-asserted-by":"publisher","first-page":"1399613","DOI":"10.3389\/fimmu.2024.1399613","volume":"15","author":"J Zhang","year":"2024","unstructured":"Zhang J, Yu J, Yang D, Jiang L, Dong X, Liu Z, Yu R, Yu H, Shi A (2024) Bevacizumab reduces cerebral radiation necrosis due to stereotactic radiotherapy in non-small cell lung cancer patients with brain metastases: an inverse probability of treatment weighting analysis. Front Immunol 15:1399613. https:\/\/doi.org\/10.3389\/fimmu.2024.1399613","journal-title":"Front Immunol"},{"key":"5826_CR23","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.ijrobp.2009.12.061","volume":"79","author":"VA Levin","year":"2011","unstructured":"Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Grewal J, Prabhu S, Loghin M, Gilbert MR, Jackson EF (2011) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79:1487\u20131495. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.12.061","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5826_CR24","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/COC.0b013e31829c3139","volume":"38","author":"NH Sadraei","year":"2015","unstructured":"Sadraei NH, Dahiya S, Chao ST, Murphy ES, Osei-Boateng K, Xie H, Suh JH, Peereboom DM, Stevens GH, Ahluwalia MS (2015) Treatment of cerebral radiation necrosis with bevacizumab: the Cleveland clinic experience. Am J Clin Oncol 38:304\u2013310. https:\/\/doi.org\/10.1097\/COC.0b013e31829c3139","journal-title":"Am J Clin Oncol"},{"key":"5826_CR25","doi-asserted-by":"publisher","first-page":"125043","DOI":"10.1016\/j.wneu.2026.125043","volume":"212","author":"KH Ahn","year":"2026","unstructured":"Ahn KH, Canisia Marcelina CD, Park JM, Park SJ, Kim YJ, Moon KS, Kim IY, Jung S, Jung TY (2026) Efficacy of Short-Course Bevacizumab for Brain Tumor Radiation Necrosis with a Volumetric Analysis. World Neurosurg 212:125043. https:\/\/doi.org\/10.1016\/j.wneu.2026.125043","journal-title":"World Neurosurg"},{"key":"5826_CR26","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.3171\/2022.2.JNS212006","volume":"137","author":"SR Dashti","year":"2022","unstructured":"Dashti SR, Kadner RJ, Folley BS, Sheehan JP, Han DY, Kryscio RJ, Carter MB, Shields LBE, Plato BM, La Rocca RV, Spalding AC, Yao TL, Fraser JF (2022) Single low-dose targeted bevacizumab infusion in adult patients with steroid-refractory radiation necrosis of the brain: a phase II open-label prospective clinical trial. J Neurosurg 137:1676\u20131686. https:\/\/doi.org\/10.3171\/2022.2.JNS212006","journal-title":"J Neurosurg"},{"key":"5826_CR27","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/cas.16053","volume":"115","author":"M Gao","year":"2024","unstructured":"Gao M, Wang X, Wang X, Niu G, Liu X, Zhao S, Wang Y, Yu H, Huo S, Su H, Song Y, Wang X, Zhuang HQ, Yuan ZY (2024) Can low-dose intravenous bevacizumab be as effective as high-dose bevacizumab for cerebral radiation necrosis? Cancer Sci 115:589\u2013599. https:\/\/doi.org\/10.1111\/cas.16053","journal-title":"Cancer Sci"},{"key":"5826_CR28","doi-asserted-by":"publisher","unstructured":"Tijtgat J, Calliauw E, Dirven I, Vounckx M, Kamel R, Vanbinst AM, Everaert H, Seynaeve L, Van Den Berge D, Duerinck J, Neyns B (2023) Low-dose bevacizumab for the treatment of Focal Radiation Necrosis of the Brain (fRNB): a Single-Center Case Series. Cancers (Basel) 15. https:\/\/doi.org\/10.3390\/cancers15092560","DOI":"10.3390\/cancers15092560"},{"key":"5826_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noag153","author":"J Duerinck","year":"2026","unstructured":"Duerinck J, Van Den Bent M, Brandal P, Minniti G, Galldiks N, Franceschi E, Geurts M, Berghoff AS, Renovanz M, Brandsma D, Snijders TJ, Weller M, Short SC, Platten M, Le Rhun E, Preusser M, Schweizer L, Albert NL, Furtner J, Razis E (2026) The European Association for Neuro-oncology (EANO) Consensus Statement on Radiation Necrosis. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noag153","journal-title":"Neuro Oncol"},{"key":"5826_CR30","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","volume":"15","author":"W Taal","year":"2014","unstructured":"Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15:943\u2013953. https:\/\/doi.org\/10.1016\/S1470-2045(14)70314-6","journal-title":"Lancet Oncol"},{"key":"5826_CR31","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","volume":"377","author":"W Wick","year":"2017","unstructured":"Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, von Deimling A, Golfinopoulos V, Bromberg JC, Platten M, Klein M, van den Bent MJ (2017) Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med 377:1954\u20131963. https:\/\/doi.org\/10.1056\/NEJMoa1707358","journal-title":"N Engl J Med"},{"key":"5826_CR32","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN, Consortium RE (2019) The REDCap consortium: Building an international community of software platform partners. J Biomed Inf 95:103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208","journal-title":"J Biomed Inf"},{"key":"5826_CR33","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf 42:377\u2013381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010","journal-title":"J Biomed Inf"},{"key":"5826_CR34","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1002\/cncr.25945","volume":"117","author":"S Kirste","year":"2011","unstructured":"Kirste S, Treier M, Wehrle SJ, Becker G, Abdel-Tawab M, Gerbeth K, Hug MJ, Lubrich B, Grosu AL, Momm F (2011) Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: a prospective, randomized, placebo-controlled, double-blind pilot trial. Cancer 117:3788\u20133795. https:\/\/doi.org\/10.1002\/cncr.25945","journal-title":"Cancer"},{"key":"5826_CR35","doi-asserted-by":"publisher","unstructured":"Abikenari M, Sjoholm MA, Liu J, Nageeb G, Ha JH, Wu J, Ren A, Sayadi J, Lim J, Cho KB, Verma R, Medikonda R, Banu M, Lim M (2025) Molecular and biophysical remodeling of the blood\u2013brain barrier in glioblastoma: mechanistic drivers of tumor\u2013neurovascular crosstalk. Front Phys 13. https:\/\/doi.org\/10.3389\/fphy.2025.1723329","DOI":"10.3389\/fphy.2025.1723329"},{"key":"5826_CR36","doi-asserted-by":"publisher","first-page":"v133","DOI":"10.1093\/noajnl\/vdab123","volume":"3","author":"KE Blethen","year":"2021","unstructured":"Blethen KE, Arsiwala TA, Fladeland RA, Sprowls SA, Panchal DM, Adkins CE, Kielkowski BN, Earp LE, Glass MJ, Pritt TA, Cabuyao YM, Aulakh S, Lockman PR (2021) Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases. Neuro-Oncology Adv 3:v133\u2013v143. https:\/\/doi.org\/10.1093\/noajnl\/vdab123","journal-title":"Neuro-Oncology Adv"},{"key":"5826_CR37","doi-asserted-by":"publisher","first-page":"922181","DOI":"10.3389\/fncel.2022.922181","volume":"16","author":"P Solar","year":"2022","unstructured":"Solar P, Hendrych M, Barak M, Valekova H, Hermanova M, Jancalek R (2022) Blood-Brain Barrier Alterations and Edema Formation in Different Brain Mass Lesions. Front Cell Neurosci 16:922181. https:\/\/doi.org\/10.3389\/fncel.2022.922181","journal-title":"Front Cell Neurosci"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05826-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05826-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05826-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:04:19Z","timestamp":1793754259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05826-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5826"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05826-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-10795946\/v1","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"23 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"12"}}